TaiMed Biologics, Inc. engages in the new drug development for human immunodeficiency virus (HIV). Its products include: (1) TMB-355 for the latter part of acquired immune deficiency syndrome (AIDS) medication. (2) TMB-360/365 for anti-AIDS virus. (3) TMB-607 Protease inhibitors for the anti-AIDS virus. The company was founded by David Ho, LanBo Chen and Ing-Wen Tsai on September 4, 2007 and is headquartered in Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company